A2-Breath of Life International Pharma Ltd-Autism spectrum disorder-Neuropathic pain

**A2** is an insufficiently characterized cannabinoid-based drug-program label associated in supplied metadata with Breath of Life International Pharma. Publicly available sources verify that BOL Pharma has developed cannabis-derived products containing cannabidiol and delta-9-tetrahydrocannabinol for clinical research, including a completed Phase 2 autism spectrum disorder study and early inhaled cannabinoid product development for chronic neuropathic pain. However, no concrete public source located identifies **A2** itself as a unique BOL formulation, establishes its active-ingredient composition, or confirms that it is the same product used in those programs.